Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland. Show more
Location: 910 Clopper Road, Gaithersburg, MD, 20878, United States | Website: https://altimmune.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
338M
52 Wk Range
$2.90 - $11.16
Previous Close
$3.83
Open
$3.81
Volume
2,601,466
Day Range
$3.57 - $3.83
Enterprise Value
170.8M
Cash
183.1M
Avg Qtr Burn
-20.39M
Insider Ownership
0.78%
Institutional Own.
43.29%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Metabolic dysfunction-associated steatohepatitis (MASH) Suspected Mover™ Susp. Mover™ | Phase 2b Data readout | |
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Alcohol Use Disorder | Phase 2 Data readout | |
Pemvidutide (ALT-801) (GLP-1R/GCGR) Details Alcohol-Associated Liver Disease | Phase 2 Data readout | |
Phase 2 Update | ||
T-COVID Details COVID-19 | Failed Discontinued | |
HepTCell Details Chronic hepatitis B | Failed Discontinued | |
AdCOVID Details COVID-19 | Failed Discontinued | |
NasoVAX Details Influenza | Failed Discontinued | |
NasoShield (Vaccine) Details Anthrax, Bacterial infection | Failed Discontinued |